Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monika Engelhardt

Showing results (91-100 of 227) with videos related to

Pageof 23
Sort By:
Haematologica|July 2, 2013
BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapyDominik Schnerch, Andrea Schmidts, Marie Follo, et al.
Haematologica|August 16, 2023
In-depth cytogenetic and immunohistochemical analysis in a real world cohort - reconsidering the role of primary and secondary aberrations in multiple myelomaSina Wenger, Milena Pantic, Gabriele Ihorst, et al.
Anticancer Research|December 25, 2009
Superiority of magnetic resonance imaging over conventional radiographs in multiple myelomaMonika Engelhardt, Martina Kleber, Alex Frydrychowicz, et al.
Haematologica|May 2, 2018
Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutionsMonika Engelhardt, Georg W Herget, Giulia Graziani, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
CarfilzomibMonika Engelhardt, Magdalena Szymaniak-Vits, Stefanie Ajayi, et al.
European Journal of Haematology|October 10, 2024
Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL PatientsTim Strüßmann, Philipp Hermes, Gabriele Ihorst, et al.
Cancer|June 1, 2021
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohortSophia Scheubeck, Gabriele Ihorst, Katja Schoeller, et al.
Leukemia & Lymphoma|June 29, 2010
Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcomeBa Thanh-Truc Ngo, Julia Felthaus, Manuel Hein, et al.
Haematologica|August 31, 2019
Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patientSarolta Bojtine Kovacs, Jingting Luan, Sandra Maria Dold, et al.
Annals of Hematology|September 21, 2024
Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor boardEsther Dreyling, Gabriele Ihorst, Heike Reinhardt, et al.
Pageof 23

Showing results (91-100 of 227) with videos related to

Sort By:
Pageof 23
Haematologica|July 2, 2013
BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapyDominik Schnerch, Andrea Schmidts, Marie Follo, et al.
Haematologica|August 16, 2023
In-depth cytogenetic and immunohistochemical analysis in a real world cohort - reconsidering the role of primary and secondary aberrations in multiple myelomaSina Wenger, Milena Pantic, Gabriele Ihorst, et al.
Anticancer Research|December 25, 2009
Superiority of magnetic resonance imaging over conventional radiographs in multiple myelomaMonika Engelhardt, Martina Kleber, Alex Frydrychowicz, et al.
Haematologica|May 2, 2018
Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutionsMonika Engelhardt, Georg W Herget, Giulia Graziani, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
CarfilzomibMonika Engelhardt, Magdalena Szymaniak-Vits, Stefanie Ajayi, et al.
European Journal of Haematology|October 10, 2024
Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL PatientsTim Strüßmann, Philipp Hermes, Gabriele Ihorst, et al.
Cancer|June 1, 2021
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohortSophia Scheubeck, Gabriele Ihorst, Katja Schoeller, et al.
Leukemia & Lymphoma|June 29, 2010
Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcomeBa Thanh-Truc Ngo, Julia Felthaus, Manuel Hein, et al.
Haematologica|August 31, 2019
Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patientSarolta Bojtine Kovacs, Jingting Luan, Sandra Maria Dold, et al.
Annals of Hematology|September 21, 2024
Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor boardEsther Dreyling, Gabriele Ihorst, Heike Reinhardt, et al.
Pageof 23